Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fentanyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.98 |
| ▸ | MAOA | P21397 | 1/20 | 0.98 |
| ▸ | DRD4 | P21917 | 1/20 | 0.98 |
| ▸ | MAOB | P27338 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | HRH1 | P35367 | 1/20 | 0.98 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fentanyl SCHEMBL8804 | 0.99 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL916599 | 0.99 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4321837 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL28383546 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL242876 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL18249370 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4324385 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4353786 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL22637301 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4326756 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066366-B2 | Hydrophilic fentanyl derivatives | ALLEGHENY-SINGER RESEARCH INSTITUTE (US) | 2021-07-20 | — | — | US | disclosed |
| US-20180273475-A1 | HYDROPHILIC FENTANYL DERIVATIVES | ALLEGHENY-SINGER RESEARCH INSTITUTE | 2018-09-27 | — | — | US | disclosed |
| WO-2017041095-A1 | HYDROPHILIC FENTANYL DERIVATIVES | ALLEGHENY-SINGER RESEARCH INSTITUTE (US) | 2017-03-09 | — | — | WO | disclosed |
| CN-101889981-A | The stable liposome compositions that comprises the lipophilic amine that contains ingredient | DELEX THERAPEUTICS INC | 2010-11-24 | — | — | CN | disclosed |
| CN-1893926-B | Stable liposome composition comprising lipophilic amine containing pharmaceutical ingredient | DELEX THERAPEUTICS INC | 2010-09-08 | — | — | CN | disclosed |
| EP-1689364-A4 | STABLE LIPOSOME COMPOSITIONS COMPRISING LIPOPHILIC AMINE CONTAINING PHARMACEUTICAL AGENTS | YM BIOSCIENCES INC (CA) | 2008-10-29 | — | — | EP | disclosed |
| US-20070269502-A1 | Stable Liposome Compositions Comprising Lipophilic Amine Containing Pharmaceutical Agents | DELEX THERAPEUTICS INC. (CA) | 2007-11-22 | — | — | US | disclosed |
| EP-1759691-A1 | Stable liposome compositions | Delex Therapeutics Inc. (CA) | 2007-03-07 | — | — | EP | disclosed |
| CN-1893926-A | Stable liposome composition comprising lipophilic amine containing pharmaceutical ingredient | DELEX THERAPEUTICS INC (CA) | 2007-01-10 | — | — | CN | disclosed |
| EP-1689364-A1 | STABLE LIPOSOME COMPOSITIONS COMPRISING LIPOPHILIC AMINE CONTAINING PHARMACEUTICAL AGENTS | Delex Therapeutics Inc. (CA) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005048986-A1 | STABLE LIPOSOME COMPOSITIONS COMPRISING LIPOPHILIC AMINE CONTAINING PHARMACEUTICAL AGENTS | DELEX THERAPEUTICS INC. (CA) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273475-A1 | HYDROPHILIC FENTANYL DERIVATIVES | OPRD1, OPRK1, OGFR | OPRM1 4/4885OPRD1 1/4885OPRK1 2/4885 |
| US-11066366-B2 | Hydrophilic fentanyl derivatives | OPRD1, OPRK1, OGFR | OPRM1 4/4885OPRD1 1/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.